कंपनी का अवलोकन
Embecta Corp. operates as a medical device manufacturer dedicated to enhancing the health and wellbeing of individuals managing diabetes across the United States and international markets. The firm functions within the healthcare sector, specifically targeting the medical instruments and supplies industry, which implies a focus on essential equipment for patient care and treatment administration. Embecta maintains a substantial operational scale, employing 1850 individuals and holding a total market capitalization of $525.28M. This entity generates annual revenue of $1.08B, positioning it as a mid-sized player in the specialized medical technology landscape. The valuation indicates a company with significant revenue generation capabilities relative to its market cap, suggesting a mature business model with established distribution channels for its pen needles, syringes, and safety injection devices.
वित्तीय स्वास्थ्य
The company reported revenue of $1.08B over the trailing twelve months, accompanied by net income of $139.50M and EBITDA of $366.70M. The substantial gap between the $1.08B revenue and the $139.50M net income reveals a highly efficient cost structure where operating expenses and taxes consume approximately 87.1% of total sales, leaving a robust profit margin. Embecta demonstrates strong financial flexibility with free cash flow reaching $188.91M, indicating the ability to fund operations and potentially return capital without immediate reliance on external financing. Profitability analysis shows a gross margin of 63.2%, an operating margin of 29.2%, and a profit margin of 12.9%, reflecting high efficiency in production and strong control over operating costs relative to revenue. Regarding liquidity and leverage, the firm holds $201.30M in cash against $1.41B in debt, while the debt-to-equity ratio is listed as N/A, suggesting a capital structure that relies heavily on equity or alternative financing mechanisms rather than traditional leverage. The current ratio stands at 2.64, which indicates a healthy short-term liquidity position where current assets significantly exceed current liabilities. Return metrics include a return on assets of 18.4%, while return on equity is listed as N/A, revealing that the company generates significant returns on the asset base available for operations.
मूल्यांकन आकलन
Valuation metrics for Embecta show a P/E ratio of 3.76 on a trailing twelve-month basis and a forward P/E of 3.08. The lower forward P/E relative to the trailing P/E implies that the market expects earnings growth or a multiple contraction that would justify the valuation in the coming period. The price-to-book ratio is negative at -0.86, which indicates that the market values the company at less than its book value, a scenario often seen in asset-heavy or distressed situations, though Embecta's profitability suggests a specific accounting context for this metric. Alternative valuation multiples include a price-to-sales ratio of 0.49 and an EV/EBITDA of 4.73, suggesting the stock is priced conservatively relative to its sales and earnings power. The stock trades within a 52-week range bounded by a high of $15.55 and a low of $8.47, meaning the current price sits below the 52-week high, reflecting recent market volatility. The beta value is 1.10, indicating that the stock's price volatility is slightly higher than the broader market, making it more sensitive to overall market fluctuations than a beta of 1.0 would suggest.
Growth & Income
Growth metrics indicate a revenue growth rate of -0.3% year-over-year, while earnings growth is listed as N/A, suggesting that the company is currently stabilizing revenue rather than expanding rapidly. The negative revenue growth implies a contraction in sales volume or pricing pressures, yet the maintenance of high profitability margins allows the firm to remain profitable despite this stagnation. As a dividend payer, Embecta offers a dividend yield of 6.8% with a payout ratio of 25.4%, which indicates a highly sustainable payout given that only a quarter of earnings are distributed to shareholders. This low payout ratio combined with high free cash flow suggests the company retains most of its earnings for reinvestment in research, development, or debt reduction rather than distributing all profits. The overall growth and income profile presents a value-oriented investment case characterized by stable profitability, a high current yield, and a market capitalization that reflects a mature stage in the business lifecycle rather than a high-growth expansion phase.